Clinical Trials Showing that a “Sufficient Percentage” of Prescriptions Will Practice Claimed Method Held to Prove Induced Infringement
Judge Du of the District of Nevada recently issued findings of facts and conclusions of law in a patent trial related to the drug Vascepa®. Amarin Pharma, Inc. v. Hikma Pharma. USA Inc. The court ultimately held that the asserted claims were all invalid as obvious. But first it held that defendants proposed labels would…